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Abstract
Lithium (Li), valproate (VPA) and lamotrigine (LTG) are commonly used to treat bipolar disorder (BD). While their clinical
efficacy is well established, the mechanisms of action at the molecular level are still incompletely understood. Here we
investigated the molecular effects of Li, LTG and VPA treatment in induced pluripotent stem cell (iPSC)-derived neural
precursor cells (NPCs) generated from 3 healthy controls (CTRL), 3 affective disorder Li responsive patients (Li-R) and 3 Li
non-treated patients (Li-N) after 6 h and 1 week of exposure. Differential expression (DE) analysis after 6 h of treatment
revealed a transcriptional signature that was associated with all three drugs and most significantly enriched for ribosome and
oxidative phosphorylation (OXPHOS) pathways. In addition to the shared DE genes, we found that Li exposure was
associated with 554 genes uniquely regulated in Li-R NPCs and enriched for spliceosome, OXPHOS and thermogenesis
pathways. In-depth analysis of the treatment-associated transcripts uncovered a significant decrease in intron retention rate,
suggesting that the beneficial influence of these drugs might partly be related to splicing. We examined the mitochondrial
respiratory function of the NPCs by exploring the drugs’ effects on oxygen consumption rate (OCR) and glycolytic rate
(ECAR). Li improved OCR levels only in Li-R NPCs by enhancing maximal respiration and reserve capacity, while VPA
enhanced maximal respiration and reserve capacity in Li-N NPCs. Overall, our findings further support the involvement of
mitochondrial functions in the molecular mechanisms of mood stabilizers and suggest novel mechanisms related to the
spliceosome, which warrant further investigation.
Introduction
Bipolar disorder (BD) is an affective disorder with a pre-
valence of 2–3% in the general population [1]. It is a
debilitating illness characterized by recurring episodes of
depression and mania or hypomania. Among the most
widely prescribed and studied medications for treating BD
is lithium (Li), which has a full response rate of about 30%
[2]. Li prevents recurrence of both manic and depressive
episodes, and is the first-line treatment for long-term
maintenance phase [3]. Valproate (VPA) is a leading
alternative mood stabilizer, being most effective against
mania [4]. Lamotrigine (LTG) is also a commonly pre-
scribed mood stabilizer, which shows a greater efficacy for
preventing and ameliorating depressive episodes rather than
mania [5]. In addition to BD, both Li [6] and VPA [7] may
also have beneficial effect in major depressive disorder
(MDD).
Multiple studies have investigated the molecular effects
of mood stabilizers in neuronal cells, and several putative
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mechanisms of action have been suggested [8–10]. For
example, Li has been found to selectively reverse an early
hyperexcitable phenotype in young neurons derived from Li
responders [10]. Furthermore, Li reduces dopamine and
glutamate levels and increases inhibitory neurotransmitters-
related signals (e.g., GABA) [8]. It also inhibits glycogen
synthase kinase-3β activity [11], which has been linked to
the drug’s anti-manic properties [9]. Similarly, VPA
appears to act by reducing the activity of NMDA-glutamate
receptors and by enhancing GABAergic neurotransmission
[12]. In contrast, LTG does not seem to modify any of these
targets, its main mode of action being the blockage of
voltage-gated sodium channels [13]. Interestingly, long-
term treatment with Li and VPA was found to protect
against methamphetamine-induced mitochondrial dysfunc-
tion and toxicity in animal models [14] and enhance cell
respiration rate in a neuroblastoma cell line, as determined
by measurements of mitochondrial membrane potential and
mitochondrial oxidation [15]. At the transcriptional level,
the molecular effects of mood stabilizers, Li in particular,
have been studied in different experimental models,
including animal models [16], neuroblastoma cells [17],
neurons [18] and peripheral lymphoblastoid cell lines
derived from BD patients [19]. These studies have
demonstrated widespread effects on diverse cellular sig-
naling pathways related to apoptosis, immune functions,
protein processing and response to endoplasmic reticulum
stress [19].
However, little attention has been directed to the tran-
scriptional and functional effects of mood stabilizers in
neural precursor cells (NPCs), which seem to have been
undervalued, despite the fact that they exhibit neuron-like
mitochondrial and energy metabolism properties [20], are
the major cell type in the subventricular zone of the lateral
ventricle and subgranular zone of the hippocampal dentate
gyrus and are essential for the generation of new neurons
through neurogenesis [21]. For example, aberrant adult
neurogenesis in the dentate gyrus has been implicated in
MDD [22]. Interestingly, some studies have demonstrated
that Li increases neurogenesis in the dentate gyrus of rodent
hippocampus in addition to influencing the proliferation and
differentiation of NPCs in hippocampus both in vitro and
in vivo [23]. Hence, it has been suggested that the stimu-
lation of endogenous NPCs may explain why Li is asso-
ciated with thicker cortex and larger subcortical volumes in
BD patients [24]. Furthermore, iPSC-derived NPCs have
been shown to be appropriate models for the study of
mitochondrial diseases [20], for phenotypic and tran-
scriptomic characterization [25], neurotoxicity [26] and
expression-based drug screening in psychiatric disorders
[27]. Hence, in this study, we investigated the effects of Li,
VPA and LTG in iPSC-derived NPCs generated from
patients with affective disorder (BD and MDD), with a
particular focus on transcriptional and mitochondrial
mechanisms. Our findings unveil a noteworthy spliceosome
boost triggered equally by all three drugs as well as a Li and
VPA-induced improvement of mitochondrial respiration.
Methods
Patient samples
Skin biopsy donors were recruited through the Norwegian
TOP (Thematically Organized Psychosis) study. Informa-
tion about recruitment procedures, inclusion and exclusion
criteria and clinical assessments for the TOP study as a
whole have been described in detail elsewhere [28]. For
reprogramming and NPC differentiation, fibroblasts were
isolated from 3 healthy controls (CTRLs) and 6 patients
with affective disorder that were selected based on clinical
information. Supplementary Table 1 summarizes the clin-
ical characteristics of the study participants. Patients
experiencing no symptoms or only mild symptoms during
Li treatment (patients #4-#6) were considered Li responders
(Li-R), while the other patients (#1-#3) were considered
non-treated (Li-N) (Supplementary Table1). The group of
Li-responders included a partial responder (patient#4), as
during some periods poor Li compliance was indicated.
Skin biopsies were obtained under sterile conditions from
the 9 donors. All participants have given written consent
and the study was approved by the Norwegian Data Pro-
tection Agency and the Regional Ethics Committee of the
South-Eastern Norway Regional Health Authority (REK
grant: #2012/2204). The authors assert that all procedures
contributing to this work comply with the ethical standards
of relevant guidelines and regulations.
IPSC derivation
Fibroblasts isolated from CTRL and patient donors were
grown and expanded in vitro in DMEM 10% fetal bovine
serum, 1% penicillin streptomycin and 1% Glutamax. Cells
were then reprogrammed with Sendai virus, transduced with
the CytoTune™-iPS 2.0 Sendai Reprogramming Kit
(ThermoFisher) containing Oct4, Sox2, Klf4, and c-Myc
reprogramming factors. Virus was washed after 24 h. At
7 days after transduction cells were plated on Vitronectin
and medium was changed to Essential 8 Flex Medium
(ThermoFisher). Passaging of iPSCs was done every
3–4 days or at a maximum of 80% confluency by using
EDTA 0,5mM for 3–5 min at 37 °C. Cells were split in 1:3
ratio on Geltrex-coated plates in the presence of 10µM
ROCK inhibitor Y-27632 (Miltenyi Biotec). Complete virus
elimination was corroborated in iPSCs at passage 10 by RT-
PCR with specific SeV genome detection primers (TaqMan
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Mr04269880-mr, ThermoFisher). Each iPSC line was sub-
jected to rigorous quality control at the Norwegian Core
Facility for Human Pluripotent Stem Cell Research Centre,
including phenotyping, regular monitoring of morphology
and pluripotency marker expressions.
IPSCs differentiation to NPCs
IPSCs from CTRLs and patients were differentiated into
neural precursor cells (NPCs) following a previously pub-
lished protocol [29] with some modifications. First, iPSCs
on Geltrex-coated plates at a 15–20% density were differ-
entiated to neuroepithelium with rosette formation in A-
DMEM/F12, 1% penicillin streptomycin, 1% Glutamax and
1% N2 with the addition of SB431542, LDN193189 and
XAV-939 (dual SMAD inhibition and Wnt inhibition). At
day 7, rosette-like structures were isolated with Rosette
Selection Reagent (Stemcell technologies) and 9x105cells/
well were plated on laminin coated plates. NPCs were then
cultured in A-DMEM/F12, 1% P/S, 1% Glutamax, 1% N2
and 0,4% B27 supplemented with FGF2 at 2,5ng/ml
changing the medium every other day during 5–6 days.
NPCs were then passaged and cultured in A-DMEM/F12,
1% P/S, 1% Glutamax, 1% N2, 0,1% B27 in hypoxic
conditions (3% O2) on laminin coated 6-well plates. Basal
medium was equilibrated in the incubator O/N and FGF2
was added fresh daily to the cells to a final concentration of
10ng/ml. Cells were passaged with accutase (Sigma) every
4–5 days.
Immunofluorescence
IPSCs and NPCs grown in chamber slides (ThermoFisher,
#177437) were fixed with 4% paraformaldehyde in PBS for
20 min, permeabilized with 0,2% Triton X-100 in PBS and
blocked in 6% donkey serum for 1hour. Then, cells were
incubated with primary and secondary antibodies. Primary
antibodies used were: anti-Nestin (mouse, 1:1000, Stem
Cell Technologies, 60091.1); anti-Sox1 (rabbit, 1:1000,
Stem Cell Technologies, 60095); anti-Sox2 (rabbit, 1:200,
Stemgent, 09–0024); anti-Oct4 (mouse, 1:200, Stem Cell
Technologies, 60093.1) and anti-Nanog (rabbit, 1:200,
Stemgent, 09–0020). Secondary antibodies (Alexa Fluors,
ThermoFisher) were anti-rabbit Alexa 488 (1:200, Invitro-
gen, A32790) and anti-mouse Alexa 594 (1:200, Invitrogen,
A21203). Nuclei were stained with 4′,6-diamidino-2-phe-
nylindole (DAPI, Roche, 10236276001) and then cover
glasses (VWR, ECN631-1575) were mounted on top with
Fluoromount-G (Invitrogen, #00-4958-02). Images were
acquired using a Zeiss LSM 700 confocal microscope and
were processed using Fiji software. Fields based on uniform
DAPI staining were selected. 300 cells were analyzed for
each NPC marker from all lines.
Real-time quantitative PCR
Cells were lysed directly in their wells by adding lysis
buffer. Total RNA was extracted with the RNeasy Plus Mini
kit (Qiagen, #74136) following the manufacturer’s instruc-
tions. Reverse transcription of 0.5 μg total RNA to cDNA
was performed with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, #4368814). The
cDNA was then used for real-time quantitative PCR with
Power SYBR Green Master Mix following the manu-
facturer’s instructions (Applied Biosystems). All reactions
were carried out on a QuantStudio 12K Flex Real-Time PCR
System (Applied Biosystems). Relative mRNA expression
was calculated as ratios normalized against GAPDH by
using the 2−ΔΔCt method. Primers used for iPSCs and NPCs
characterization are specified in Supplementary Table 2.
Drug administration
IPSC-derived neural precursor cells from all 9 donors were
expanded until passage 4–5 and then treated with 1 mM Li
(Sigma, #4408), 30 µM VPA (Sigma, P4543), 25 µM LTG
(Tocris, #1611) (all three diluted in DMSO) or 0.1% DMSO
alone (vehicle control). In all cases, the clinically recom-
mended therapeutic serum concentrations for the drugs were
used. For LTG and VPA, the concentrations in vitro were
reduced compared to the recommended in vivo concentra-
tions, because when treating patients it is necessary to
increase the concentration to compensate for the drug loss
due to plasma protein binding, estimated to be 50 and 90%,
respectively. We treated the NPCs from all donors with all
three mood stabilizers, regardless of their prescribed treat-
ments, to identify shared mechanisms of action using cells
with the same genetic background. Treatment duration was
6 h and 1 week, with medium and drug refreshment on a
daily basis for the 1 week condition.
RNA extraction and sequencing
Total RNA was extracted from all 72 samples (DMSO, Li,
VPA, and LTG treatment for each of the 9 donors at two
time points) with the RNeasy Plus Mini Kit (Qiagen).
Approximately 1 million cells were used as input. RNA
yield was quantified with a NanoDrop 8000 Spectro-
photometer (NanoDrop Technologies) and RNA integrity
was assessed with Bioanalyzer 2100 RNA 6000 Nano Kit
(Agilent Technologies). All samples had an RNA Integrity
Number (RIN) above 8.5. Library preparation and paired-
end RNA-sequencing were carried out at the Norwegian
High-Throughput Sequencing Centre (www.sequencing.
uio.no). Briefly, libraries were prepared with the TruSeq
Stranded mRNA kit from Illumina which involves Poly-A
purification to capture coding as well as several non-coding
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RNAs. The prepared samples were then sequenced on an
Illumina NovaSeq SP platform at an average depth of 50
million reads per sample using a read length of 100 base
pairs and an insert size of 350 base pairs.
Data processing
Raw sequencing reads were quality assessed with FastQC
(Babraham Institute). To pass the initial QC check, the
average Phred score of each base position across all reads had
to be at least 30. Reads were further processed by cutting
individual low-quality bases and removing adapter and other
Illumina-specific sequences with Trimmomatic V0.32 using
default parameters [30]. HISAT2 [31] was then used to first
build a transcriptome index based on ENSEMBL annotations,
and then to map the trimmed reads to the human GRCh38
reference genome. To quantify gene expression levels, map-
ped reads were summarized at the gene level using feature-
Counts [32] guided by ENSEMBL annotations.
Cell type deconvolution and differential expression
(DE) analysis
Bioinformatical estimation of cell type abundances
(deconvolution) was carried out with CIBERSORTx [33]
using the web-interface (https://cibersortx.stanford.edu/)
with default parameters, selecting 500 permutations for
statistical testing. Expression signatures for 8 relevant cell
types from Burke et al. [34]. were used as reference: iPSCs,
NPCs, fetal replicating neurons, fetal quiescent neurons,
oligodendrocyte progenitor cells (OPCs), adult neurons,
astrocytes, and oligodendrocytes. Before conducting the DE
analyses, genes with very low to zero expression were
removed by filtering out any gene with ≤0.5 counts per
million (CPM) in 3 or more samples (the smallest group
size). Since two of the patient lines (#5 and #6) had a partial
chromosomal loss on chromosome 6 encompassing ~7000
kb, all genes within this deleted region were also excluded.
For DE analyses, limma-voom [35] was used. Since a
paired design was used, all variables were perfectly matched
across groups and no covariates were included. For the DE
analyses, age and NPC abundance were adjusted for. In all
analyses, a DE gene was considered significant if the FDR
was <0.10. Pathway analyses of significant DE gene sets
were conducted with the over-representation analysis tool
clusterProfiler [36] using the enrichKEGG function after
removing pathways related to human diseases. A pathway
was considered significantly enriched if the FDR was <0.10.
Enrichment analysis in human brain regions
To test whether the treatment-specific DE genes were
enriched in any specific brain region, ABAEnrichment [37]
was used. This tool uses two human brain expression
datasets (adult and developmental) provided by the Allen
Brain Atlas [38, 39] and assigns to each anatomical struc-
ture the genes that are expressed in that structure by
applying an expression threshold. It then performs ontology
gene set enrichment analyses to identify significant overlaps
between a custom-provided list of input genes and the genes
that are expressed in a specific brain area using either a
hypergeometric test or a Wilcoxon-rank sum test. Three
cutoff quantiles (0.5, 0.7, 0.9) were used to annotate genes
to brain regions, and the Wilcoxon-rank sum test and the
“adult” dataset were selected for the enrichment analyses.
By default, all enrichment analyses were adjusted for mul-
tiple testing using the family-wise error rate (FWER)
approach. Enriched brain areas were visualized with the R
package cerebroViz [40].
Intron retention rate (IRR) quantification
To detect retained introns and estimate the IRR, we used
IRFinder [41], which implements an end-to-end analysis of
intron retention from RNA-sequencing data. The BAM files
generated after mapping of sequencing reads with HISAT2
were used as input. Differential intron expression analysis
was performed with the DESeq2 package [42] and the IRR
was defined as the ratio between intronic reads and the sum
of intronic and normally spliced reads. A change in IRR
between DMSO and drug-treated samples (Li, VPA, LTG)
was considered significant if the magnitude of the change
was no less than 20% and the FDR < 0.05.
KaryoStat assay
KaryoStat GeneChip array (ThermoFisher) was used for
karyotyping of iPSCs at passages 15–20. It allows for
digital visualization of chromosome aberrations with a
resolution similar to g-banding karyotyping. The size of
structural aberration that can be detected is >2Mb for
chromosomal gains and >1Mb for chromosomal losses.
The array covers all 36,000 RefSeq genes, including 14,000
OMIM® targets with an optimized low-resolution DNA
copy number analysis. The assay enables the detection of
aneuploidies, submicroscopic aberrations, and mosaic
events. Genomic DNA (gDNA) was extracted using the
Genomic DNA Purification Kit (Catalog #: K0512) and
quantified using the Qubit dsDNA BR Assay Kit (Catalog
#: Q32850). For GeneChip preparation a total of 250 ng
gDNA was processed according to manufacturer’s instruc-
tions. Briefly, Nsp I digested gDNA was ligated, PCR
amplified, fragmented, labeled with biotin and hybridized
onto a GeneChip array overnight. Chips were washed and
stained using GeneChip Fluidics Station 450 and scanned
using GeneChip Scanner 3000 7 G. The raw data was
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processed using Chromosome Analysis Suite 3.2 with
NetAffx na33.1 (UCSC GRCh37/hg19). Output data were
interpreted with the UCSC Genome Browser (https://
genome.ucsc.edu/; GRCh37/hg19 assembly).
Mitophagy assay
Mitophagy levels were analyzed in all 9 lines after 6 h and
1 week of 1 mM Li stimulation using the Mitophagy
detection kit (Dojindo Molecular Technologies, #MD01-
10). Briefly, Mitophagy Dye was added to the cells at 100
nmol/l and incubated for 30 min at 37 °C. The Dye accu-
mulates in intact mitochondria and is immobilized through
chemical bonds. During mitophagic damage induction, the
injured mitochondria fuses to lysosomes and then Mito-
phagy Dye emits a high fluorescence intensity [43]. Cells
were analyzed by flow cytometry in a Gallios Flow Cyt-
ometer 10 colors, 4 lasers from Beckman Coulter. Data was
analyzed with Gallios flow cytometry software.
Bioenergetic assessment
Cellular bioenergetics assessment of cells was performed
using a Seahorse XFe24 extracellular flux analyzer
(Agilent Seahorse XF Analyzers), as described previously
[20]. Briefly, 50,000 cells were plated into each Geltrex-
coated well of the XFe24-well plates and incubated at
37 °C overnight with 5% CO2. Then, growth medium was
replaced with unbuffered media and cells were incubated
for 60 min at 37 °C in a non-CO2 incubator to allow the
media to reach equilibrium of temperature and pH before
starting recording data. Both mitochondrial respiration
(OCR or oxygen consumption rate) and anaerobic gly-
colysis (ECAR or extracellular acidification rate) mea-
surements were recorded simultaneously. Baseline levels
were first recorded and then 4 different chemical inhibi-
tors (all at 1 μM and from Sigma) were added to test
mitochondrial respiration function. All experiments
were performed in technical quadruplicates. First, oligo-
mycin, a complex V blocker, was added to inhibit
oxidative phosphorylation (OXPHOS) and test respiration
coupling to ATP synthesis. Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (CCCP), a proto-
nophore uncoupling agent, was added to decrease the
mitochondrial membrane potential (MMP), thus increas-
ing respiration rate and enabling the quantification of the
maximal respiration under maximal mitochondrial
uncoupling. The last compounds to be added were rote-
none, a blocker of the complex I, and antimycin A, a
blocker of the complex III, which cause complete inhi-
bition of mitochondrial respiration, therefore allowing us
to examine the non-respiratory oxygen consumption.
Values were normalized to the total protein content in
each well of the plate using the BCA protein assay kit
(ThermoFisher, #23225).
Statistics
Data are presented as mean ± SD for the iPSC and NPC
characterization by RT-PCR and mitophagy assay results;
and as mean ± SEM for the Seahorse results. In vitro
mitophagy assay results represent mean values of duplicate
measurements and Seahorse values represent the mean from
quadruplicate measurements. Comparisons between groups
were done by analysis of variance (ANOVA) between
groups for the initial IRR analysis (F statistic and p value
are shown in the figures). For the Seahorse parameters,
ANOVA was used to compare the mean values of more
than two groups, and two-tailed unpaired t-test was used to
compare differences in drug treatment.
Results
Differentiation of iPSCs to NPCs
Fibroblasts from skin biopsies were obtained from 3 healthy
controls (CTRL) and 6 affective disorder patients, of whom
3 were Li responders (Li-R) and 3 were Li non-treated
(Li-N). The fibroblasts were reprogrammed to iPSCs using
Sendai virus, and differentiated to NPCs following a pre-
viously published protocol [29]. NPC samples were sub-
sequently treated with Li, VPA, and LTG, and RNA-seq
was used for gene expression profiling (Fig. 1). All three
groups were matched with respect to gender (2 females and
1 male per group). Details about donor age, gender, and
diagnostic subtype are provided in Supplementary Table 1.
The iPSCs were characterized by immunofluorescence,
RT-PCR, and alkaline phosphatase staining for assessment
of pluripotency marker expression, as well as karyotyping
for genomic integrity testing. All iPSC lines expressed the
pluripotency markers Oct4, Sox2, Nanog and AP (Fig. 2a–d
and Supplementary Fig. 1a, b). Karyotyping revealed a near-
identical partial loss in two of the patient lines (#5 and #6) at
the 6q24.3 locus (Fig. 2c and Supplementary Fig. 1c).
Deletions within the 6q24-25 region have been previously
linked to both BD and suicidal behavior [44], and this region
encompasses several genes which are implicated in BD,
such as SYNE1 or ZDHHC14 [45]. The size of the detected
region was 6913 kb and 6992 kb in the two lines, respec-
tively, and included ~30 genes with detectable expression
levels in the NPCs (Supplementary Fig. 2a). Consequently,
these genes were excluded before conducting the DE
analyses.
Next, one iPSC clone from each donor was differentiated
into NPCs by dual SMAD and Wnt inhibition and
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characterized at both mRNA and protein levels (Fig. 2e–g).
All NPC cultures displayed high mRNA expression of
the essential markers NESTIN, PAX6, SOX1, and SOX2
(Fig. 2e). CTRL NPCs exhibited moderate expression of
SOX1 mRNA compared to patient NPC lines, while also
showing slightly higher SOX2 levels, but no statistically
significant differences were detected between CTRL and
patients (Fig. 2e). Donor NPCs also displayed high levels of
EMX2 and MSI1 (Fig. 2e), which are expressed pre-
dominantly in proliferating multipotent neural precursor
cells in the adult brain in regions such as the dentate gyrus
[46, 47]. In addition, cells showed low expression of OTX1
(Fig. 2e, which regulates neural progenitor cells in the
developing cortex [48]. At the protein level, characteristic
NPC markers were expressed by all NPC lines, and their
phenotype was further validated by immunofluorescence of
NESTIN, SOX2, and SOX1 at passage 3–4 after rosette
selection, with no observable morphological differences
between patient and CTRL cells (Fig. 2f, g and Supple-
mentary Fig. 2b), indicating a successful generation of
iPSC-derived NPCs.
Transcriptomic characterization of NPC cultures and
effect of mood stabilizers
Having established that the iPSC-generated cells display
typical NPC markers, the short-term (6 h and 1 week)
transcriptional effects of Li, VPA, and LTG treatment on
global gene expression were assessed. The relatively short
treatment durations were chosen, as longer drug exposure
would require additional passaging of the NPCs, which may
change the cellular phenotype.
Principal component analysis (PCA) showed clear
separation on donor when clustering across the first two
principal components (PCs), explaining most of the varia-
tion in gene expression (Fig. 3a, c; Supplementary Fig. 2c).
The importance of donor effects in iPSC studies is well
established [49]. Within each cluster, regardless of the type
of treatment, treatment duration had a large impact on gene
expression (Fig. 3e). This observation highlights the need
to include separate control samples (DMSO) for each
duration (Supplementary Fig. 2c). A weak tendency of
clustering on diagnosis (CTRL vs. patients) was seen when
Control iPSCs Li-N iPSCs Li-R iPSCs 9 iPSC lines 
+ Valproate [30μM]+ Lithium [1mM] + Lamotrigine [25μM] DMSO
9 NPC lines Control NPCs Li-R NPCsLi-N NPCs
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Fig. 2 Characterization of iPSCs and NPCs. a Representative
images of iPSC immunofluorescence staining for one line from each
group (CTRL, Li-N and Li-R). Nuclear Oct4 and Nanog pluripotency
markers are shown in the merged image. Cell nuclei were stained with
DAPI. Scale bars: 100 µm. b Key pluripotency marker alkaline
phosphatase (AP) staining positively in iPSC colonies from one line
representative of each group used in the study. Scale bars: 100 µm.
c Karyotype for one representative line from each group assessed by
KaryoStat™ analysis. Somatic and sex chromosomes are displayed
together. The y-axis shows the log2 ratios depicting the microarray
probe’s signal intensities. A CN value of 2 represents a normal copy
number state. Chromosomal gains are represented by a value of 3,
while chromosomal losses are represented by a value of 1. Pink, green
and yellow colors indicate each individual chromosome probe´s raw
signal. The blue line represents the normalized probe signal used to
identify copy number aberrations. The same ~7000 kb partial chro-
mosomal loss was detected in 2 patient lines (#5 and #6) on chro-
mosome 6 at position q24.3 (see also Supplementary Fig. 1c). d Real-
time PCR analysis of the pluripotency marker genes OCT4, SOX2 and
NANOG in CTRL and patient-derived iPSCs compared to H9
embryonic stem cells (H9 ESCs) expression levels. Data is presented
as mean ± SD. e Real-time PCR characterization of NPC marker genes
NESTIN, PAX6, SOX1, SOX2, MSI1, EMX2, and OTX1. Values are
given for mRNA expression levels relative to fibroblasts. Data is
presented as mean ± SD. f NPC immunofluorescence staining for
Nestin, Sox1 and Sox2. Scale bars: 100 µm. g Percentage of cells
staining positive for Nestin, Sox2 and Sox1 by counting 300 cells from
the immunofluorescence analysis of each line. No differences were
found between groups.
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clustering across PCs 3 and 4, accounting for a smaller
portion of the total variation (Fig. 3b, d). These findings
were generally confirmed by variance partition analysis,
which also attributed relatively small effects to RNA-seq
batch, Li response status, and gender (Fig. 3e). Importantly,
age had the third largest contribution to gene expression
variation, which is in line with previous publications
showing age as an influential factor in iPSC models [50],
underscoring the necessity of adjusting for age differences
in DE analyses.
Since differences in cell type proportions are another
major source of gene expression variance [49], we used
computational deconvolution to estimate the abundances
of 8 relevant brain cell populations. As expected, NPCs
constituted the largest fraction of cells in the cultures, but
other cell types were also present (Fig. 3f). In particular, a
relatively high proportion of fetal replicating neurons
were detected, suggesting transcriptional similarities
between our cell cultures and early progenitor stages
(16–18 weeks post-conception) of fetal brain tissue.
Although none of the differences in cell type composition
between groups were statistically significant, we adjusted
for NPC proportion in the DE analyses due to a higher
median estimate in Li-R samples compared to Li-N
and CTRLs.
Genes modulated by mood stabilizers are enriched
in cerebellar brain regions and involved in ribosome
and oxidative phosphorylation pathways
To investigate how common mood stabilizers modulate
gene expression, and how this modulation is affected by
disease and Li response status, three sets of DE analyses
were carried out: 1) The first set consisted of DE analyses
between DMSO and mood stabilizer treatment (Li, VPA,
LTG) combining both CTRL and patient samples, with the
aim of identifying genes whose expression profile is asso-
ciated with the drug treatment per se (treatment-associated
genes). 2) The second set consisted of DE analyses between
DMSO and drug treatment in patients only, to identify DE
genes that are specifically regulated in patients upon drug
exposure (treatment-patient-associated genes). 3) The third
set consisted of DE analyses between Li treatment and Li
response status (Li-N vs. Li-R), to identify genes that are
differentially expressed in Li-R but not in Li-N patients
after Li treatment (Li-response-associated genes).
After 6 h of treatment with Li, VPA, and LTG, a sub-
stantial effect on gene expression was found, with 9557
(54%), 7965 (45%), 8353 (47%) DE genes being significantly
associated (FDR < 0.1) with each of the drugs, respectively. In

















































































Fig. 3 Transcriptomic characterization of NPC cultures. a–d
Principal component analysis (PCA) plots of all samples based on the
1000 most variant genes. Most variation in gene expression is
explained by donor effects. Within each cluster, treatment duration
per se, i.e., regardless of the type of treatment, has a big effect on gene
expression, underscoring the importance of including separate control
samples (DMSO) for both duration categories. e Variance partition
plot showing the proportion of gene expression variance attributed to
different sources. Residuals constitute additional, unknown sources of
variation not accounted for. f Cell type proportions estimated by
computational deconvolution. NPCs and fetal replicating neurons were
the cell populations with largest fractions, but other cell types are also
present in the cultures. No significant differences between groups were
found for any cell type. Fetal_replicating: Replicating neuronal pro-
genitors (from fetal brain tissue, 16–18 weeks post-conception).
Fetal_quiescent: Quiescent newly born neurons (from fetal brain
tissue, 16–18 weeks post-conception). OPC oligodendrocytes
precursor cells.
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genes were up-regulated and the other half was down-
regulated (Fig. 4a). Moreover, 5558 genes were associated
with all three drugs (Li∩VPA∩LTG), indicating a large
overlap in their gene expression signatures (Fig. 4b). To
examine whether the identified DE genes are over-represented
in any specific brain regions, we performed human brain
enrichment analysis using the top 1000 DE genes as input.
Genes uniquely associated with Li were significantly enriched
(FDR < 0.05) in several brain structures, including the cin-
gulate gyrus (CNG), thalamus (THA), and cerebellum (CB)
(Fig. 4c; Supplementary Table 3), while LTG and VPA-
associated unique DE genes were not enriched in any brain
regions. However, the set of overlapping DE genes were
enriched in multiple cerebellar structures, such as several
regions of the vermis and posterior lobe and the left lateral
hemisphere (Fig. 4d; Supplementary Table 4), suggesting a
shared effect of all three drugs on the transcriptional regula-
tion of cerebellar NPCs. Pathway enrichment analysis of the
DE genes uniquely associated with each drug showed that Li-
only genes were most strongly enriched for axon guidance
processes, followed by focal adhesion, cell cycle, and RNA
transport (Fig. 4e). On the other hand, the shared DE genes
were enriched for pathways related to the ribosomal
machinery, OXPHOS, thermogenesis, endocytosis, and the
spliceosome, among others (Fig. 4e). The common associa-
tion with ribosome function is in line with previous reports
showing that Li inhibits the binding of transfer RNA to
ribosomes [51], which results in a reversible mechanical
dissociation of the ribosome into 50S and 30S subunits.
Likewise, it has been shown that LTG treatment may lead to a
rapid accumulation of immature 30S and 50S ribosomal
subunits in bacteria [52].
Spliceosome
Endocytosis
Protein processing in endoplasmic reticulum




























Fig. 4 Treatment-specific DE genes and downstream analyses after
6 h and 1 week of exposure. a Volcano plots of DE genes for each
treatment (Li, VPA and LTG) vs. DMSO after 6 h of exposure. b Venn
diagram of DE genes after 6 h of exposure. The majority of DE genes
were shared between all three treatments. c Enrichment of 6 h Li-
specific genes in human brain structures. d Enrichment of 6 h shared
DE genes in human brain structures. e Pathway (KEGG) analysis of
DE genes (1670) that were unique to Li treatment (purple) and DE
genes (5558) that were shared (gray) between all three treatments. The
DE genes uniquely associated with VPA (540) and LTG (1431) were
not enriched for any pathways. f Volcano plots of DE genes associated
with VPA and LTG treatment vs. DMSO after 1 week of exposure. Li
treatment for 1 week did not result in any significant DE gene. g Venn
diagram of DE genes associated with 1 week LTG and VPA treat-
ments. h Enrichment of 1 week LTG genes in brain regions. i Pathway
(KEGG) analysis of unique LTG genes. No significantly enriched
pathway was identified for unique VPA genes. VPA valproate, LTG
lamotrigine, DMSO dimethyl sulfoxide, KEGG the Kyoto Encyclo-
pedia of Genes and Genomes, CB cerebellum, MED medulla oblon-
gata, PON pons, SN substantia nigra, CNG anterior cingulate cortex,
DFC dorsal frontal cortex, THA thalamus.
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DE analyses were also performed after 1 week of drug
exposure (Fig. 4f–i). No DE genes were identified for Li
treatment. VPA-associated (FDR < 0.1) unique [39] and
shared (271) DE genes (Fig. 4g) were not enriched for any
pathway or brain region. However, LTG-related unique DE
genes (4381) were enriched in multiple brain stem structures
(Fig. 4h; Supplementary Table 5). These LTG genes were
also significantly associated with OXPHOS, thermogenesis,
and autophagy pathways (Fig. 4i). With regards to the DE
analyses in set 2), both 6 h and 1 week treatment resulted in
the modulation of a set of DE genes that was fundamentally
the same as the treatment-associated genes identified in 1),
except that more genes were associated with drug exposure
when both patients and CTRL were included, reflecting the
increase in power due to increased sample size.
Li-associated DE genes regulated in Li-R NPCs are
enriched in OXPHOS and spliceosome pathways
In the third set of DE analyses, we sought to identify Li-
associated DE genes with differential regulation in Li-R
NPCs compared to Li-N NPCs to elucidate the transcrip-
tional mechanisms of action of Li response. After 6 h of
treatment with Li, 464 genes were differentially expressed
in both Li-R and Li-N groups compared to CTRL, while
1059 DE genes were unique for Li-N and 554 DE genes
were unique for Li-R samples (Fig. 5a). However, these
genes were only nominally significant (p < 0.05) and did not
reach the transcriptome-wide significance threshold of FDR
< 0.1. Of the 554 unique Li-R-associated genes, 387 (70%)
were up-regulated and 167 (30%) were down-regulated
(Fig. 5b). Interestingly, these 554 Li response-associated
DE genes were enriched for spliceosome, OXPHOS, and
thermogenesis pathways (Fig. 5c), where most genes
annotated to the thermogenesis pathway are also involved in
OXPHOS. Two of the spliceosome-associates genes were
SRSF4 and SRSF5, both of which were regulated by all
three drugs (Supplementary Fig. 3a, b) and are essential
components of the splicing machinery [53].
Short-term treatment with mood stabilizers leads to
decreased intron retention rate (IRR)
As spliceosome was one of the pathways significantly
enriched in the shared treatment-associated genes and the
pathway with strongest association with Li response, we
investigated whether this effect was reflected in the NPC
splicing activity. Although several types of alternative
splicing exist, we examined the levels of intron retention
rate (IRR) because it is a widespread phenomenon
in mammals, affecting more than 80% of coding genes in
multiple tissues [41, 54]. An initial analysis of the overall
IRR, measured as the percentage of sequencing reads
mapping to intronic regions, showed that 6 h of exposure to
any of the drugs led to significantly lower levels of IRR,
most pronounced for Li (F= 15.4, p= 8.6e−6) (Fig. 5d).
No comparable effect for 1 week exposure was seen,
although trending differences were observed that did not
reach statistical significance (Fig. 5d). To investigate whe-
ther this drug-induced reduction in IRR was global or
confined to specific genes or genomic regions, we used
IRFinder [41] to perform an in-depth intron retention ana-
lysis. As the transcriptome-wide IRR plots show, the
decrease in IRR produced by all three drugs seems to be
global and not restricted to specific regions of the genome
(Fig. 5e–g). We also found a significant negative correlation
(p < 2.2e−16 for all drugs) between mean difference in IRR
and mRNA expression level of each gene, meaning that the
more up-regulated a transcript is in drug-treated vs. DMSO-
treated samples, the fewer introns are retained. To exclude
the possibility that the identified reduction in IRR was
caused by DNA contamination, we used ANOVA to assess
the distributions of intergenic, intronic, and exonic reads
across the DMSO and drug-treated samples. Differences in
intergenic proportions were not significant after correcting
for intronic fractions (F= 0.75, p= 0.53; Supplementary
Fig. 4d), indicating that the IRR findings were not driven by
genomic DNA contamination.
Li restores low mitochondrial oxygen consumption
rate (OCR) in Li-R NPCs
Pathway enrichment analysis of the shared DE genes
((Li∩VPA∩LTG), n= 5558) identified OXPHOS as one of
the pathways most significantly enriched (Fig. 4e). Among
the most significant OXPHOS-related DE genes identified
after Li treatment for 6 h were TSPO, NDUFS7, TRADD
and NDUFS8 (Supplementary Fig. 4e–h and Supplemen-
tary Table 6). OXPHOS activity is essential for the cellular
bioenergetics and is required for the mitochondrial capacity
to generate ATP. Therefore, we assessed the impact of Li,
VPA, and LTG on mitochondrial function in the three dif-
ferent groups (CTRLs, Li-R and Li-N) after 6 h and 1 week
of stimulation. We used the Seahorse XFe24 extracellular
flux analyzer, which simultaneously measures oxygen
consumption rate (OCR) and extracellular acidification rate
(ECAR) from the cell supernatant, enabling a direct quan-
tification of mitochondrial respiration and glycolysis under
basal conditions and after injection of mitochondrial dis-
ruptor compounds through drug injection ports.
We found a tendency of decreased OCR and ECAR in
NPCs from Li-R patients compared to CTRL NPCs (Fig. 6a,
b), which is in line with previous studies [55]. However, the
differences were not significant, which may be due to the
donor variability. From the OCR and ECAR kinetics graphs,
we calculated key parameters of mitochondrial respiratory
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function such as basal respiration, respiration linked to ATP
production, maximal respiration, and reserve capacity by
sequential addition of 4 mitochondria perturbing agents: oli-
gomycin, CCCP, rotenone and antimycin. After 6 h of treat-
ment, Li significantly increased basal respiration in Li-R
NPCs (Fig. 6e, g) but not in CTRL or Li-N samples (Fig. 6g
and Supplementary Fig 5a). This increased tendency was
sustained after 1 week of treatment, and in addition, a sig-
nificant increase in maximal respiration and reserve capacity
was observed (Fig. 6h, j). No significant effect on basal
glycolysis was seen in any of the conditions after Li treatment
(Fig. 6f, g, i, j). With respect to VPA and LTG treatment, no
effect on mitochondrial OCR and ECAR parameters were
seen after 6 h (Supplementary Figs. 6a–c and 7a–f). However,
1 week of VPA exposure led to an increase in maximal
respiration and reserve capacity in Li-N NPCs (Fig. 6k–m),
and 1 week of treatment with LTG led to a reduction in ATP
production in Li-N NPCs (Supplementary Fig. 7d–f).
Li treatment does not rescue increased mitophagy
in Li-N NPCs
A recent study found a dysregulation of mitophagy proteins
in peripheral blood from BD patients [56]. Mitophagy is
a b c
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Fig. 5 DE genes associated with Li treatment in responders show
enrichment for spliceosome and OXPHOS pathways. a Venn dia-
gram of DE genes associated with Li response status after Li treatment
for 6 h, showing shared DE genes (464) and unique DE genes for Li-N
(1059) and Li-R (554) NPCs. b Volcano plot of Li-R unique DE genes
(p value < 0.05). c Pathway (KEGG) enrichment analysis of Li-R
unique DE genes (554) showing significant enrichment for spliceo-
some, oxidative phosphorylation (OXPHOS) and thermogenesis
pathways. d Initial analysis of overall intron retention rate (IRR),
measured as the percentage of sequencing reads mapping to intronic
regions, in NPCs after 6 h and 1 week treatment with DMSO, Li, VPA
and LTG. 6 h of exposure led to significantly lower levels of intron
retention for all treatments, most pronounced for Li. No comparable
effect was found for 1 week exposure. F statistic and p value of
repeated measures ANOVA tests are shown. Plots displaying
transcriptome-wide per-intron IRR by chromosome location for 6 h
treatment with Li (e), VPA (f) and LTG (g). Colored dots represent
introns with significant (IR change >20% and FDR < 0.05) differences
in retention rate in drug-treated samples compared to DMSO samples.
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the selective degradation of malfunctioning mitochondria
by autophagy, which often occurs to defective mitochon-
dria and is essential for maintaining cellular viability.
Therefore, we investigated whether the increase in mito-
chondrial respiratory parameters after Li treatment
(Fig. 6e–j) was due to a reduction in mitophagy levels in
the NPCs. Interestingly, Li-N NPCs presented higher
mitophagy levels than both CTRL and Li-R NPCs (Sup-
plementary Fig. 8a). However, we did not find any
significant improvement after Li treatment neither after 6 h
nor 1 week (Supplementary Fig. 8c).
Discussion
One approach to gain insight into the molecular basis of
affective disorders is to investigate the mechanisms of

























Fig. 6 Li and VPA enhance mitochondrial OCR in patient-derived
NPCs. Analysis of oxidative phosphorylation using Seahorse Analy-
zer. a Oxygen consumption rate (OCR) kinetics graph showing that
Li-R patient NPCs present a tendency of decreased mitochondrial
OCR, which could be indicative of dysfunctional mitochondrial
function as compared to CTRL cells. b Extracellular acidification rate
(ECAR) kinetics graph displaying glycolysis activity for all three
groups. Diagram summarizing the main OCR and ECAR results after
Li (c) and VPA (d) treatments. Li treatment of Li-R NPCs lead to an
increase in maximal respiration and reserve capacity. VPA treatment
of Li-N NPCs lead to an increase in maximal respiration and reserve
capacity. e–g OCR (e) and ECAR (f) graphs for Li treatment for 6 h.
The ECAR graph shows a tendency to increase basal glycolytic
activity, but no statistically significant difference was found. g Basal
respiration, ATP production, maximal respiration, reserve capacity and
basal glycolysis after 6 h of Li treatment. Basal respiration of Li-R
cells was significantly higher after Li treatment. The means of OCR
parameters and basal glycolysis from untreated CTRL, Li-N and Li-R
cells were compared by one-way ANOVA. The means of OCR
parameters and basal glycolysis from untreated vs. treated cells for
each experimental group were compared by two-tailed unpaired t-test.
h–j OCR (h) and ECAR (i) graphs after Li treatment for 1 week.
j Basal respiration, ATP production, maximal respiration, reserve
capacity and basal glycolysis after 1 week Li treatment. Maximal
respiration and reserve capacity of Li-R cells were significantly higher
after Li treatment. k–m OCR (k) and ECAR (l) graphs for VPA
treatment for 1 week. m Basal respiration, ATP production, maximal
respiration, reserve capacity and basal glycolysis after 1 week VPA
treatment. Maximal respiration and reserve capacity of Li-N cells were
significantly higher after VPA treatment. Data was analyzed by two-
tailed unpaired t-test. All experiments were run in quadruplicates, and
values are corrected for total protein levels. Data is presented as mean
± SEM of at least two independent experiments (n= 3 cell lines/
group). NPCs neural precursor cells, CTRL control, Li-R lithium
responders, Li-N lithium non-treated, ECAR extracellular acidification
rate, OCR oxygen consumption rate.
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iPSC technologies have now made it feasible to study these
mechanisms directly in relevant and patient-derived brain
cell populations, which ensures that the disease-specific
genetic background is preserved.
Here, we used transcriptional profiling and functional ana-
lyses to study the molecular effects of three commonly used
mood stabilizers (Li, VPA, and LTG) in iPSC-derived NPCs
from healthy controls and affective disorder patients, including
both Li responders (Li-R) and Li non-treated (Li-N). Our main
objective was to explore the gene expression signatures of
these drugs using high-coverage RNA-seq, and to investigate
the extent to which these signatures overlap and how they are
related to diagnostic as well as Li response status.
Shared gene expression signature across mood
stabilizers
We observed a large number of genes and overlap of the
identified DE genes associated with all three mood stabi-
lizers (Fig. 4b, e). This is highly interesting, as three mood
stabilizers with different modes of action seem to affect a
specific set of genes, suggesting an expression signature
with high relevance for the mood stabilizing properties of
the drugs. Accordingly, we found that shared DE genes
associated with all three drugs were enriched for OXPHOS,
homologous recombination, biosynthesis of amino acids,
protein processing in endoplasmatic reticulum, endocytosis
or spliceosome pathways (Fig. 4e) among others, suggest-
ing that these shared pathways and molecular mechanisms
involved in the correct functioning of the cell may underlie
some of the essential mood-stabilizing properties of these
drugs. In order to explore a potential common functional
outcome derived from this shared expression profile, we
further investigated two of these significant pathways,
OXPHOS and spliceosome, identifying relevant functional
effects of the mood stabilizers by regulating intronic
retention (Fig. 5) and mitochondrial properties (Fig. 6).
Short-term reduction in IRR after mood stabilizers
treatment
Recent genome-wide association studies in BD, MDD and
schizophrenia have shown that most of the associated risk
variants are located in non-coding regions of the genome
[57]. Since these regions harbor many regulatory elements,
transcriptional regulatory mechanisms are likely to play a
significant role in mental disorders. Moreover, evidence
from post-mortem brain tissue studies suggests an increased
rate of dysfunctional splicing in brain samples from indi-
viduals with psychiatric disorders [58]. For instance, dis-
ruptions in the splicing machinery caused specifically by
increased SRSF3 mRNA expression have been associated
with the pathophysiology of BD [59].
Pre-mRNA splicing and alternative splicing are key
mechanisms by which the proteomic diversity of eukaryotic
genomes is expanded. In fact, mutations in pre-mRNA
molecules have been linked to splicing dysfunction that
give rise to over 200 human diseases [60]. Intron retention
(IR) is the least studied of all types of alternative splicing,
likely because these splicing events were thought to be mere
consequences of mis-splicing. In plants and unicellular
eukaryotes, IR is the most common form of alternative
splicing, and it is also a common phenomenon in mammals
[54]. Here, we show that short-term (6 h) exposure to Li,
VPA, and LTG leads to a substantial decrease in intron
retention rate (IRR) (Fig. 5d). This initial impact on IRR
seems to be an immediate effect of drug exposure as it did
not last after 1 week of treatment. Moreover, our findings
indicate that the short-term reduction in IRR is
transcriptome-wide rather restricted to specific genes or
chromosomal regions (Fig. 5e–g). It was generally assumed
that mis-splicing, leading to the retention of introns, would
have no physiological consequences other than reducing
gene expression by nonsense-mediated decay. Yet, recent
discoveries have highlighted the pivotal role that IR plays in
human biology [61, 62], emerging thus as an unexpected
generator of transcriptomic diversity in various stages of
cell differentiation in mammals [61, 62]. Therefore, even
though we did not find a long-lasting effect on IRR after
1 week, an initial boosting effect after drug treatment might
potentially be enough to induce long-lasting consequences
in the treated cells.
Interestingly, we found that SRSF4 and SRSF5, encoding
two members of the splicing factor family, were regulated
after treatment with all three drugs (Supplementary Fig. 3a,
b). SRSF5 is of particular interest as it is ubiquitously
expressed in mammals [53]. Thus, our findings indicate that
the mechanisms of action of Li, VPA, and LTG in reg-
ulating mood stabilization may partly stem from the reg-
ulation of the spliceosome and its associated genes and
consequently of IRR regulation.
Li improves mitochondrial oxygen consumption rate
(OCR)
Multiple lines of evidence suggest a possible involvement
of mitochondrial deficits in major psychiatric disorders
[10, 63] and current stem cell technology is dramatically
improving our understanding of the bioenergetics altera-
tions in these diseases [10, 25]. Accordingly, we found that
the identified DE genes associated with all three drugs
(Fig. 4e), as well as the genes associated with Li response,
were most strongly enriched for the mitochondrial
OXPHOS pathway (Fig. 5c). Mitochondria play a crucial
role in neuronal functions, especially in energy production,
calcium signaling, and the generation of reactive oxygen
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species. Although the molecular effects of mood stabilizers
on mitochondria are still not completely understood, several
studies have unraveled potential mechanisms. For example,
Li and VPA have been reported to enhance mitochondrial
function and protect against methamphetamine-induced
mitochondrial toxicity [14, 15], in line with our results of
enhanced OCR parameters (Fig. 6). Li treatment has also
been found to increase lifespan and mitochondrial energy in
C. elegans [64]. However, a recent study found no positive
effect on an abnormally low mitochondrial membrane
potential after Li treatment of iPSC-derived neurons from
BD patients [10]. Apart from VPA and Li, LTG has also
been found to have beneficial effects on mitochondrial
toxicity in mitochondrial epilepsy [65].
Mammalian cells generate ATP by mitochondrial oxida-
tive phosphorylation and non-mitochondrial glycolytic
metabolism. Using the Seahorse XFe24 extracellular flux
analyzer, we assessed the cellular bioenergetics of drug-
treated NPCs. We found that 6 h of Li treatment led to a
significant increase in basal respiration, and 1 week treatment
with Li resulted in a significant increase in maximal respira-
tion and reserve capacity only in Li-R NPCs (Fig. 6g, j).
These data suggest that Li triggers an immediate increase in
mitochondrial respiration capacity, and that this effect is
specific to Li responders and stable over time. Furthermore,
we found an increase in maximal respiration and reserve
capacity in Li-N NPCs after 1 week treatment with VPA
(Fig. 6k–m), in line with a previous study where VPA
increased basal respiration in neural progenitors NT2-N
cells [66]. This increase in mitochondrial respiration para-
meters after 1 week of treatment may explain why VPA has
become the main adjunctive treatment to Li in the treatment
of mania in BD patients [4]. In contrast, 1 week treatment
with LTG led to a decrease in ATP production (Supple-
mentary Fig. 7), which is contrary to a previous study where
LTG increased basal respiration in NT2-N cells [66]. These
apparent discrepancies may be due to the fact that a dif-
ferent cell type and drug concentration was used in
our study.
The mitochondrial electron transport chain (ETC) is a
key parameter used to evaluate mitochondrial function. It
has been reported that Li treatment in BD patients increases
the ETC complex I activity in vivo during depressive epi-
sodes [67]. In line with this, we found that Li had an up-
regulating effect on the NDUFS7 gene (Supplementary
Fig. 8), which encodes a highly conserved subunit of the
mitochondrial complex I, involved in proton translocation
[68]. Likewise, we found an increase in TSPO after Li
treatment (Supplementary Fig. 8a), which has also been
associated with complex I activity [69] and might explain
the observed increased tendency in ATP production and
other mitochondrial parameters (Fig. 6g–j). Interestingly,
previous studies have reported a dysregulation of TSPO in
peripheral blood from BD patients [56] and low NDUFS7 in
BD post-mortem tissue [70], suggestive of defective ETC
complex I. Taken together, these results suggest a key
mechanistic role of Li in mitochondrial bioenergetics. In
particular, our results support that Li enhances OCR para-
meters in Li-R patients, probably through the regulation of
mitochondrial complex I components.
Mood stabilizers affect genes enriched in
cerebellum
Even though the cerebellum only accounts for 10% of the
total brain volume, it contains 80% of all neurons [71]. His-
torically, cerebellar regions have received little attention in
pathological and imaging studies on affective disorders like
MDD and BD. However, in the last two decades there has
been a growing interest in its possible role in mood disorders
[72]. An increasing body of literature has changed the view of
the cerebellum from a structure implicated uniquely in motor
function to a region involved in cognition and emotion as well
[73]. For example, imaging studies have demonstrated the
existence of anatomical links between several cerebellar
regions and the sensorimotor and association areas of the
brain cortex [74]. Moreover, there is increasing evidence that
these cerebellum connections with cortical areas are involved
in the pathophysiology of psychiatric disorders [72].
Accordingly, we found that Li, VPA, and LTG-associated
shared DE genes were enriched in cerebellar regions (Fig. 4d
and Supplementary Table 4), suggesting that the beneficial
effect of these three drugs might partly occur in the cere-
bellum, which has previously also been linked to neurological
side effects of Li. Apart from the cerebellum, the cortex,
amygdala and hippocampus are the brain regions that are
primarily affected in BD [75]. The fact that not many cortical
regions were enriched in the treatment-associated DE genes
we identified (Fig. 4) might be explained by the fact that
NPCs are mainly found in ventricular-subventricular regions,
which we found as enriched regions instead.
Limitations of the study
This study has two main limitations: the small number of
participants, and the sub-optimal clinical phenotype of
patient’s responsiveness to Li, which need to be considered
when interpreting the results. Although definitions of out-
come vary between studies, responsiveness is typically
determined by comparing recurrence rate, duration and
severity of mood episodes before and during lithium treat-
ment. However, due to the cross-sectional design we were
not able to assess changes of illness activity. Thus current
symptom level during treatment was applied to indicate
differences in responsiveness.
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In summary, our study revealed widespread transcriptional
effects of Li, VPA, and LTG in iPSC-derived NPCs with
potential involvement in clinical drug response. While some of
these effects were unique to each drug, a substantial overlap in
the drugs’ gene expression signatures was observed, suggest-
ing that shared pathways and molecular mechanisms may
underlie the mood-stabilizing properties of these drugs. The
findings provide further support for a key role of mitochon-
drial regulation in the molecular mechanisms of mood stabi-
lizers, and suggest novel mechanisms related to the splicing
machinery and intron retention, which may be utilized as
potential targets of new therapeutic agents.
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